Company Overview
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Why Investors Should Care
Revenue has grown at a 64.2% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.19.
Recent Developments
- Dec 2025 Revenue of $15.91M (-15.9% YoY); net profit $-42.18M.
- Trailing 12 Months Year-on-year growth — revenue +120.4%.
- 5-Year Trend Long-term compounding — revenue CAGR 64.2%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 64.18% |
| 1 Year: | 120.40% |
Stock Price Performance
| 1 Year: | +1.49% |
| 6 Months: | +8.47% |
| 3 Months: | +33.99% |
| 1 Month: | +9.33% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)48.58 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 64.2% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 32.8% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PRQR ProQR Therapeutics N.V. PHARMA | 2.05 | -4.46 | $289.29M | 0.00% | -54.09% | -57.40% | 64.18% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 4.52M | 3.82M | 2.88M | 4.69M | 2.03M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 15.34M | 16.07M | 14.17M | 13.79M | 15.68M |
| Operating Income | - | -10.82M | -12.25M | -11.28M | -9.10M | -13.65M |
| EBITDA | - | -10.14M | -11.57M | -10.61M | -6.21M | -12.96M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | -10.08M | -12.16M | -11.01M | -8.92M | -13.38M |
| Tax Provision | - | 0 | 18.00K | 0 | 1.00K | 0 |
| Net Income | - | -10.08M | -12.18M | -11.01M | -8.92M | -13.38M |
| Diluted EPS | - | -0.10 | -0.12 | -0.10 | - | -0.13 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 3.59M | 6.51M | 18.91M | 15.91M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 68.75M | 41.30M | 49.38M | 59.35M |
| Operating Income | - | -65.16M | -34.79M | -30.47M | -43.45M |
| EBITDA | - | -56.46M | -24.10M | -24.12M | -38.53M |
| Interest Expense | - | 5.13M | 1.20M | 1.08M | 929.00K |
| Pretax Income | - | -64.11M | -27.81M | -27.96M | -42.16M |
| Tax Provision | - | 96.00K | -78.00K | -197.00K | 19.00K |
| Net Income | - | -64.42M | -28.12M | -27.76M | -42.18M |
| Diluted EPS | - | -0.90 | -0.35 | -0.32 | -0.40 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 171.32M | 137.88M | 167.96M | 112.76M |
| Current Assets | - | 154.46M | 120.99M | 153.84M | 100.13M |
| Cash & Equivalents | - | 94.78M | 118.92M | 149.41M | 92.41M |
| Inventory | - | - | - | - | - |
| Receivables | - | - | - | 0 | 3.36M |
| Total Liabilities | - | 104.64M | 96.49M | 79.40M | 63.38M |
| Current Liabilities | - | 20.99M | 34.20M | 38.90M | 32.44M |
| Long Term Debt | 39.32M | 4.27M | 4.29M | - | - |
| Total Debt | - | 21.97M | 19.73M | 17.22M | 15.96M |
| Total Equity | - | 67.06M | 41.39M | 88.56M | 49.37M |
| Shares Outstanding | - | 84.25M | 84.25M | 107.71M | 107.71M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -68.51M | 21.55M | -36.39M | -52.79M |
| Investing Cash Flow | - | -702.00K | 4.28M | -4.07M | -1.02M |
| Financing Cash Flow | - | -30.89M | -2.27M | 70.28M | -1.84M |
| Capital Expenditure | - | -708.00K | -1.37M | -1.42M | -1.02M |
| Free Cash Flow | - | -69.22M | 20.18M | -37.81M | -53.81M |
| Net Change in Cash | - | -100.10M | 23.55M | 29.81M | -55.65M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | -1,813.0% | -534.1% | -161.2% | -273.1% |
| Net Margin % | - | -1,792.5% | -431.7% | -146.9% | -265.2% |
| ROE % | - | -96.1% | -67.9% | -31.3% | -85.4% |
| ROCE % | - | -43.3% | -33.6% | -23.6% | -54.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Adage Capital Partners GP L.L.C. | 8.56% | 9.02M | $16.50M |
| 2 | Aberdeen Group plc | 8.48% | 8.93M | $16.35M |
| 3 | Affinity Asset Advisors, Llc | 5.26% | 5.54M | $10.15M |
| 4 | Privium Fund Management B.V. | 5.24% | 5.52M | $10.10M |
| 5 | Ikarian Capital, LLC | 3.25% | 3.43M | $6.27M |
| 6 | Woodline Partners LP | 3.11% | 3.28M | $6.00M |
| 7 | Heights Capital Management, Inc | 2.62% | 2.76M | $5.06M |
| 8 | Morgan Stanley | 1.68% | 1.77M | $3.23M |
| 9 | Sphera Funds Management Ltd. | 1.67% | 1.76M | $3.22M |
| 10 | Kynam Capital Management, LP | 1.49% | 1.57M | $2.87M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PRQR
$PRQR stock is up 8% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPem9ENVdTNE1sczFEOUZtWnpJYkdLdVg1a3ZLRTMtbTF2ZF9ZN1pGTnBsVktjRFJmNDRpSVFwNTdXUVNSLW5GRXZVWXg4eWRPeUJrSldiSGVqUzgyRlBrWGl6RTlMWGc1UHRWclV0bXJ6c1RobGlMbU52RmlFcG9HZ2M4MzZoU0pPOWh4M0…
Enterprise value to EBIT forward of ProQR Therapeutics N.V. – NASDAQ:PRQR - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxPRHRjN1lLN2xwelFWVnRtNHdtbzFKTERhaDhFUHRRV1BCTHpPeWZheWtjMC1fQlJSaVJGWXNDNHhkbk5HaDludkxFbXFsd3NDcWlObVlMZmVOWDh3a010VEZWVFZYamY2NzNUNVBMYTZ3Y2xkejV2RS1UcFRqcy0zbWdDYlVDQ0ZrdEdlaV…
ProQR Therapeutics (PRQR) Stock Rises On Revenue Surge As Losses Ease - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxQUXlCSUdqcDUtRjR4NmlITjFBU2VEWVpJRjNVbDdLaWRFREZqcVVDRWdPSVJiSm5HdHJSMGo3aERNc2ZWTWs1VXl3UEdCSHpQT2xlX3hwYU9vTFJiQlJqMXljbzF5SkVDeDVyeWN1NHZyUlgycG03MjNDd1dUcEpESnZTTlpKVWVfM29lTF…
H.C. Wainwright reiterates ProQR stock rating on platform data - Investing.com
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNbUdkSWV4akhmWmRReUs4eThkSk5wRVlDdnRDSHVGZkd4cHkxdzNLN2ZBZnNkYlF5UkQ0RDUwZy1nT1J2aWM5ZVZFU0VRSnpYeHFZUmg0UWJpMGVmT3FkWFcxYUVzTm5Fbno4bFM3SXVZQkJCMTh5YXZ4QXo4MGFleVZiWnZtSlpHNkRFTV…
ProQR Therapeutics (PRQR) Stock Rises On Revenue Surge As Losses Ease - webull.com
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE9lX2pyMVJlT1FnZFVBcGJyazZJUzFWSU9tamZkOUQwdlc1TXNYdmFnT08xX01qbnhMR0o3dUxVcEpsaFdTbHFSSlJkeEpseE9hblpoaTRBTWs?oc=5" target="_blank">ProQR Therapeutics (PRQR) Stock Rises On Revenue…
Growing Optimism About ProQR Therapeutics (PRQR)’s RNA Editing Platform and Future Clinical Catalysts - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPOXVoaDVqUUdvQU1uTklEWlh4MnpQSU9tUzc2TTFKMy1RZWNhNEEzT2k1WFVhbjIxcVJ2M1NWLWV0b2VIelNFY2gxbmh3UG1TbVdJcmVEeThONmhDQTBHU3hRQzV6OGpsTXhhTmdQbEx0cHNCNHVCTkVKdE4zVml0WkNWSUt1aEg5Slg3S0…
PRQR — Frequently Asked Questions
What is the current share price of ProQR Therapeutics N.V. (PRQR)?
As of 2026-09-19 21:16 PDT, ProQR Therapeutics N.V. (PRQR) trades at $2.05 on NasdaqCM. Its 52-week range is $1.37 to $3.05.
What is the market capitalisation of PRQR?
ProQR Therapeutics N.V. (PRQR) has a market capitalisation of $289.29M on NasdaqCM.
What is the P/E ratio of PRQR?
PRQR trades at a trailing price-to-earnings (P/E) ratio of -4.46. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.17.
What is the return on equity (ROE) of PRQR?
PRQR has a return on equity (ROE) of -57.40%. Its return on capital employed (ROCE) is -54.09%.
Is PRQR a good stock to buy?
This page provides a data-driven analysis of ProQR Therapeutics N.V. (PRQR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.